Letters to the Editor

Babesiosis and Transfusion Medicine



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2002 Jul 1;66(1) Online.

to the editor: The article by Dr. Mylonakis provides an excellent overview of the management of babesiosis.1 I would like to point out, however, that the degree of parasitemia need not always parallel the severity of clinical symptoms.2 This disparity may be attributed to some of the indirect, harmful effects related to parasitemia within the host. Usually, this is evident when anemia is disproportionate to the degree of parasitemia.3 The reason for such incongruity is related to the fact that both parasitized and healthy erythrocytes get destroyed, as a result of an infection-mediated, autoimmune, hemolytic process.The production of anti-erythrocytic autoantibodies, possibly aimed at Rh antigens on the red cell,4 explains why some persons may have a positive Coombs test during infection.

Dr. Mylonakis recommends exchange transfusion, together with antibabesial chemotherapy, for critically ill patients with a blood parasitemia of more than 10 percent, massive hemolysis and asplenia.1 Indeed, prompt institution of exchange transfusion, in combination with appropriate drug therapy, can be life-saving; however, reliance solely on the level of parasitemia or the degree of hemolysis alone to advocate this form of therapy may be misleading, for the reasons alluded to above. Cases that are refractory to appropriate antibiotic therapy may also respond to exchange transfusion. Moreover, exchange transfusion may be of value to persons who cannot tolerate drugs because of toxicities or adverse effects. Transfusions are not to be recommended for routine management because of the hazards posed by multiple blood exposures. The benefits of this treatment, however, clearly outweigh the risks when it is clinically indicated. Until controlled trials are available to clarify the specific indications, merit and goals of exchange transfusion in the management of babesiosis, clinical judgment is probably still the best guide.

REFERENCES

1. Mylonakis E. When to suspect and how to monitor babesiosis. Am Fam Physician 2001;63:1969-74.

2. Sun T, Tenenbaum MJ, Greenspan J, Teichberg S, Wang RT, Degnan T, et al. Morphologic and clinical observations in human infection with Babesia microti. J Infect Dis1983;148:239-48.

3. Carson CA, Phillips RS. Immunologic response of the vertebrate host to babesia. In: Babesiosis. Ristic M, Kreier JP, eds. New York: Academic Press;1981.

4. Wolf CF, Resnick G, Marsh WL, Benach J, Habicht G. Autoimmunity to red blood cells in babesiosis. Transfusion 1982;22:538-9.

in reply: I would like to thank Dr. Pantanowitz for his interest in my article. In his letter, Dr. Pantanowitz suggests that "clinical judgment" is the best guide for the use of exchange transfusion in the management of babesiosis. I wholeheartedly agree, and this is stated clearly and unequivocally in my paper.1

Dr. Pantanowitz also writes that "exchange transfusion may be of value to persons who cannot tolerate drugs because of toxicities or adverse effects."I would like to caution care providers that the use of exchange transfusion without antimicrobial chemotherapy is untested. The appropriate management of patients who are ill enough to require exchange transfusion and cannot tolerate an antimicrobial regimen is to try another regimen, not to use exchange transfusion alone. In a large study among patients with babesiosis, 97.5 percent of patients were able to complete a course of azithromycin with atovaquone with excellent results,2 and a number of other treatment options are available.

REFERENCES

1. Mylonakis E. When to suspect and how to monitor babesiosis. Am Fam Physician 2001;63:1969-74.

2. Krause PJ, Lepore T, Sikand VK, Gadbaw J JR, Burke G, Telford SR 3d, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000;343:1454-8.

Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.


Copyright © 2002 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article